Spectral Medical (EDT) Price & Analysis

Compare

19 Followers

EDT Stock Chart & Stats

C$1.38

-C$0.01(-1.75%)

At close: Jan 08 4:00 PM EST

C$1.38

-C$0.01(-1.75%)

Day’s Range― - ―

52-Week RangeC$0.63 - C$1.84

Previous CloseN/A

Volume37.78K

Average Volume (3M)78.93K

Market Cap

C$374.48M

Enterprise ValueC$388.05M

Total Cash (Recent Filing)C$5.89M

Total Debt (Recent Filing)C$20.96M

Price to Earnings (P/E)―

Beta0.80

Next Earnings

Mar 26, 2026

EPS Estimate

-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.11

Shares Outstanding292,562,930

10 Day Avg. Volume98,063

30 Day Avg. Volume78,934

Financial Highlights & Ratios

PEG Ratio3.66

Price to Book (P/B)-5.10

Price to Sales (P/S)61.48

P/FCF Ratio-15.89

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Revenue GrowthThe company has demonstrated significant revenue growth, which indicates increasing demand for its products and potential market expansion.

Market DemandRising sepsis cases and focus on advanced therapeutics enhance demand for Spectral Medical's core product, supporting long-term growth.

Strategic PartnershipsCollaborations with medical institutions and companies can enhance product offerings and expand market reach, supporting sustainable growth.

Bears Say

Financial StabilityNegative equity and rising debt levels indicate potential solvency issues, which could limit the company's ability to invest in growth.

Cash Flow ChallengesPersistent negative cash flow suggests difficulties in sustaining operations without external financing, impacting long-term viability.

Profitability ConcernsOngoing losses and negative profit margins highlight operational challenges, questioning the company's ability to achieve profitability.

Spectral Medical News

Spectral Medical Reports Positive Trial Results and Revenue Growth

Spectral Medical (Edtxf) ( ($EDTXF) ) has released its Q3 earnings. Here is a breakdown of the information...

3M ago

Spectral Medical Reports Positive Tigris Trial Results and Prepares for FDA Submission

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced positive results from its Phase 3...

3M ago

Spectral Medical Files Base Shelf Prospectus to Raise $100 Million

Spectral Medical ( ($TSE:EDT) ) has issued an announcement. Spectral Medical Inc. has filed a final short form...

5M ago

Spectral Medical’s Study Highlights High-Risk Septic Shock Subgroup, Bolstering PMX Therapy Rationale

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced the publication of a study in...

5M ago

Spectral Medical Sponsors Unite for Sepsis Symposium, Highlights Personalized Treatment

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical Inc. announced its sponsorship of the Unite...

5M ago

Spectral Medical Secures US$3 Million Funding to Advance Sepsis Treatment

Spectral Medical ( ($TSE:EDT) ) has provided an update. Spectral Medical Inc. has received a US$3 million Tranche...

6M ago

Spectral Medical Advances Toward FDA Approval for PMX

Spectral Medical (Edtxf) ( ($EDTXF) ) has released its Q2 earnings. Here is a breakdown of the information...

6M ago

Spectral Medical’s Tigris Trial Shows Promising Results for Septic Shock Therapy

Spectral Medical ( ($TSE:EDT) ) has provided an announcement. Spectral Medical and Vantive announced positive topline results from...

6M ago

Spectral Medical Advances Towards FDA Approval with Tigris Trial Progress

Spectral Medical ( ($TSE:EDT) ) just unveiled an update. Spectral Medical announced significant progress in its clinical and...

6M ago

Spectral Medical Files Base Shelf Prospectus for Financial Flexibility

Spectral Medical ( ($TSE:EDT) ) has provided an announcement. Spectral Medical Inc. has filed a preliminary short form...

8M ago

EDT FAQ

What was Spectral Medical’s price range in the past 12 months?

Spectral Medical lowest stock price was C$0.63 and its highest was C$1.84 in the past 12 months.

What is Spectral Medical’s market cap?

Spectral Medical’s market cap is C$374.48M.

When is Spectral Medical’s upcoming earnings report date?

Spectral Medical’s upcoming earnings report date is Mar 26, 2026 which is in 35 days.

How were Spectral Medical’s earnings last quarter?

Spectral Medical released its earnings results on Nov 07, 2025. The company reported -C$0.11 earnings per share for the quarter, missing the consensus estimate of -C$0.01 by -C$0.1.

Is Spectral Medical overvalued?

According to Wall Street analysts Spectral Medical’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spectral Medical pay dividends?

Spectral Medical pays a Notavailable dividend of C$0.12 which represents an annual dividend yield of N/A. See more information on Spectral Medical dividends here

What is Spectral Medical’s EPS estimate?

Spectral Medical’s EPS estimate is -0.01.

How many shares outstanding does Spectral Medical have?

Spectral Medical has 292,562,930 shares outstanding.

What happened to Spectral Medical’s price movement after its last earnings report?

Spectral Medical reported an EPS of -C$0.11 in its last earnings report, missing expectations of -C$0.01. Following the earnings report the stock price went down -0.694%.

Which hedge fund is a major shareholder of Spectral Medical?

Currently, no hedge funds are holding shares in TSE:EDT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spectral Medical

Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.